@prefix this: . @prefix sub: . @prefix drugbank: . @prefix np: . @prefix mondo: . @prefix pav: . @prefix infores: . @prefix xsd: . @prefix ntemplate: . @prefix orcid: . @prefix rdfs: . @prefix pmid: . @prefix ncit: . @prefix rdf: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { drugbank:DB00334 a biolink:Drug; rdfs:label "Olanzapine"; biolink:category biolink:Drug . mondo:0005618 a biolink:Disease; rdfs:label "Anxiety disorder"; biolink:category biolink:Disease . sub:association rdf:object mondo:0005618; rdf:predicate biolink:treats; rdf:subject drugbank:DB00334; a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation; rdfs:label "First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics"; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation; biolink:has_population_context sub:context; biolink:publications pmid:31077503; biolink:relation ncit:C94303 . sub:context a biolink:Cohort; rdfs:label "Adults"; biolink:category biolink:Cohort . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB"; npx:hasSignature "V3wh44U5u0/9ZQtSh0QEZ9nYSwotFjRsGnzFdyoRh73/L9cql/W3A6XPijNCT/KITVrkcbspW/i50nJKwDPHLAqH2TWqLxlh5LBGBRVAchdOxIdqqDcAYTqruZY31vmZroosgbMKkIDOOruHfAGk8euBoVIDGgJXK6kynzeqZH4="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-09-16T11:51:08.822166"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-1501-1082; ntemplate:wasCreatedFromTemplate . biolink: pav:version "2.3.0" . }